A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma
- 5 April 2007
- journal article
- Published by Springer Nature in Leukemia
- Vol. 21 (7) , 1545-1548
Abstract
Osteonecrosis of the jaw (ONJ) is a reported complication of bisphosphonate use. The incidence ranges between 6 and 13% and seems to be higher in people treated with zoledronic acid (ZA) than with pamidronate. We retrospectively evaluated the incidences of ONJ and skeletal-related events (SRE) in 106 patients with multiple myeloma divided in two groups according to the schedule of administration of bisphosphonates: 51 received monthly administrations until tolerated (group A, standard schedule), 55 were treated monthly during the first year and then every 3 months (group B, reduced schedule). The incidence of SRE was similar (15.1 per 100 person years in group A and 17.7 in group B). ONJ occurred in seven patients, six in group A and one in group B (P=0.049). The risk of ONJ was eight-fold lower with the reduced schedule than with the standard schedule. The only significant risk factor for ONJ was the type of bisphosphonate (P=0.006). The incidence of ONJ was significantly higher with ZA than with pamidronate + ZA (9.1 vs 1.6 per 100 person-years). No ONJ was observed in patients treated only with pamidronate. A reduced schedule of ZA may be safer than the standard schedule while maintaining anti-resorptive efficacy.Keywords
This publication has 14 references indexed in Scilit:
- Osteonecrosis of the Jaw and BisphosphonatesNew England Journal of Medicine, 2005
- Pathogenesis of myeloma bone diseaseBlood Cells, Molecules, and Diseases, 2004
- Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemicJournal of Oral and Maxillofacial Surgery, 2003
- Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinomaCancer, 2003
- Review of 1027 Patients With Newly Diagnosed Multiple MyelomaMayo Clinic Proceedings, 2003
- Zoledronic acid in the treatment of hypercalcemia of malignancy: Results of the international clinical development programSeminars in Oncology, 2001
- Long-term pamidronate treatment of advanced multiple myeloma patients reduces skeletal events. Myeloma Aredia Study Group.Journal of Clinical Oncology, 1998
- Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple MyelomaNew England Journal of Medicine, 1996
- Preclinical pharmacology of CGP 42′446, a new, potent, heterocyclic bisphosphonate compoundJournal of Bone and Mineral Research, 1994
- Osteoclast inhibition for the treatment of bone metastasesCancer Treatment Reviews, 1993